| Literature DB >> 15135718 |
Kathryn A Glatter1, Qing Wang, Mark Keating, Shenghan Chen, Nipavan Chiamvimonvat, Melvin M Scheinman.
Abstract
We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15135718 DOI： 10.1016/j.amjcard.2004.02.023
Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778